US EditionPublished • loading... • Updated
Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars
Eli Lilly projects $80–$83 billion revenue and raised EPS guidance for 2026 due to strong demand for GLP-1 drugs Zepbound and Mounjaro, surpassing analyst estimates.
- On Wednesday, Eli Lilly and Company posted fourth-quarter results and raised its 2026 guidance to $80 billion–$83 billion, with adjusted earnings guidance.
- Surging demand for GLP-1 drugs such as Zepbound and Mounjaro underpins the stronger outlook, while November pricing deals are expected to boost prescriptions for Medicare and Medicaid beneficiaries.
- Lilly CEO Dave Ricks said `a step down in pricing` will occur, while fourth quarter results showed adjusted EPS $7.54 and revenue $19.29 billion beat estimates.
- The deals shift commercial math by pairing price cuts with tariff relief, granting a three-year tariff exemption while Novo Nordisk warned on Tuesday of sales declines as exclusivity ends in China, Brazil and Canada.
Insights by Ground AI
8 Articles
8 Articles
Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars
Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as the world's most valuable drugmaker prepares to launch its oral weight-loss pill later this year.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources8
Leaning Left1Leaning Right0Center5Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
